Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series
Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series
复制标题
DOI：
10.1055/s-0029-1237375
复制
发表时间：
2010-01-01
影响因子：
4.3
通讯作者：
Deuschle, M.
中科院分区：
文献类型：
--
作者：
Paslakis, G.;Gilles, M.;Deuschle, M.
我们打算在4例抑郁症患者中评估1.25 mg/kg口服S-氯胺酮作为标准抗抑郁药的添加治疗的安全性、治疗反应和反应时间。两名抑郁症患者早期反应并保持缓解，而两名具有明显躯体症状、慢性或非典型特征的患者没有反应。由于患者数量有限，无法得出疗效结论。口服S-氯胺酮耐受性良好，由于其实用性高于（S-）氯胺酮输注治疗，因此值得在随机对照试验中进行研究。应考虑临床亚型。
We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow conclusions about efficacy. Oral S-ketamine was well tolerated and could merit being studied in randomised controlled trials due to its higher practicability compared to (S-)ketamine infusion therapy. Clinical subtyping should be considered.